Medtech company DermaSensor has claimed FDA approval for a handheld device, powered by artificial intelligence (AI), that can be used to detect skin cancer at the point of care. The eponymous ...
Checkpoint Therapeutics’ late entry into the PD-1/PD-L1 inhibitor category, cosibelimab, just got knocked back even further after it was turned down by the FDA as a treatment for skin cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback